Survival in multiple myeloma has improved significantly with the advent of novel, more potent immunotherapies, including CAR ...

Bispecific antibodies show strong initial uptake in community settings for multiple myeloma treatment, particularly among ...

A new review published in Blood Cancer Discovery outlines a major multiple myeloma research project that supported a key ...

A high-fiber, plant-based diet delays progression to multiple myeloma, improves microbiome health, reduces inflammation, and ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...

Anita D'Souza, MD, discusses some of the potentially practice-changing data that were presented at the 2024 ASH Annual ...

Today researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from the first ever clinical trial to show ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Legend Biotech (LEGN) has released an update. Legend Biotech’s CARVYKTI® has demonstrated a significant improvement in minimal residual disease negativity for multiple myeloma patients compared to ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...